The short version of lyophilized powder fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-05. Anything still debated is marked as such rather than presented as settled.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Enslavement in the Americas existed before European arrival and was used for numerous reasons. Slavery in Mexico can be traced back to the Aztecs. Other Amerindians, such as the Inca of the Andes, the Tupinambá of Brazil, the Creek of Georgia, and the Comanche of Texas, also practiced slavery. Slavery in Canada was practiced by First Nations and by European settlers. Slave-owning people of what became Canada were, for example, the fishing societies, such as the Yurok, that lived along the Pacific coast from Alaska to California, on what is sometimes described as the Pacific or Northern Northwest Coast. Some of the indigenous peoples of the Pacific Northwest Coast, such as the Haida and Tlingit, were traditionally known as fierce warriors and slave-traders, raiding as far as California. Slavery was hereditary, the slaves being prisoners of war and their descendants were slaves. Some nations in British Columbia continued to segregate and ostracize the descendants of slaves as late as the 1970s.
==== Polish ==== Alliance of Poles in America - Founded on September 22, 1895, in Ohio as Alliance of Poles. Added "of America" in 1914. Headquarters in Cleveland. Locals are called "Groups", regional groups "Circles", and the national structure is the "Central Body", which meets quadrennially. Membership is open to both sexes from the start. Now open to anyone 15–65, of good moral character, physically and mentally healthy, Polish or Lithuanian by birth or consanguinity. Has no ritual, but it does have an oath. Had 16,000 in the late 1960s, and 20,000 in 72 locals in 1979. Had 20,000 members in 1994. Federal Life Insurance of America - Founded in 1911 as a pressure group with the US Catholic church for Polish interests. Its original name was the Federation of Polish Catholic Laymen. The insurance aspect was added in 1913, and the name changed to the Federation of Poles in America. Became Federal Life Insurance of America in 1924. Local groups are called "Lodges"; in 1979 there were 28 lodges in 7 states. The national convention meets quadrennially. Poles or people of Polish descent are eligible. A women's division was added in 1940. There were 5,000 members in 1960, and 5,543 in 1979. There were 4,476 in 1994. Sent food and clothing to Poland and Polish refugees during World War II; aided the Ochronka Orphanage in Poland since the war; also supports International Folk Fair in Milwaukee. Polish Beneficial Association - Founded in 1899 in Philadelphia and headquartered there. Locals are called "groups". National convention meets quadrennially.
Photograph C. – Open rhinoplasty: After the preliminary taping of the nose, a custom-made, metal nasal-splint, designed, cut, and formed by the surgeon, is emplaced to immobilize and protect the tender tissues of the new nose during convalescence. Photograph D. – Open rhinoplasty: The taping, emplacement of the metal splint, and dressing of the new nose complete the rhinoplasty procedure. The patient then convalesces, and the wound dressing will be removed at 1-week post-procedure.
By March 2002, the Yorkshire-Tricon multi-branding test consisted of 83 KFC/A&Ws, six KFC/Long John Silver's, and three Taco Bell/Long John Silver's and was considered successful by the companies. In December 2000, A&W announced new openings in less conventional locations, such as casinos, airports, gas stations, convention centers and convenience stores, for 2001, as part of its growth plans. At the time, the chain had more than 1,000 locations in 47 states and over 200 international locations in 14 countries. The chain around the time emphasized its aesthetics on "contemporized nostalgia". It also saw a success in co-branded restaurants, following the success of a trial in Butte in 1998, which, owing to its success, in the spring of 2000 led to the announcement of the opening of 300 joint KFC-A&W restaurants by 2005. Tricon bought both A&W and LJS in March 2002, shortly before the merger with Yorkshire was finalized.
Historically, the birth rate of teenagers peaked in the late 1950s and early 1960s. However, at that time, most teenage parents were married. In the early twenty-first century, nine in ten births to the age group 15-19 are to unmarried mothers. Social norms have changed; it is now not unusual for teenagers to delay or avoid sexual intercourse altogether. Younger teenagers are more likely to practice abstinence than their older counterparts. A report published by the Center for Disease Control and Prevention (CDC) in early 2018 found the number of high school students who have had sex fell from 47% in 2005 down to 41% in 2015, with the most dramatic drop taking place between 2013 and 2015. On top of that, among never-married teens who have had sex, overwhelming majorities reported they used contraception the first time they did it. There are a few reasons for this. First, Millennials and Generation Z are more focused on the consequences of sex than their predecessors were. Second, there has been growing concern over unwanted sexual advances, especially in the wake of the Me-too movement. Writing for The Spectator, Douglas Murray dubbed this the "sexual counter-revolution." Third, as a consequence of the precarious contemporary economy, young adults today are more likely to be living with their parents rather than on their own, with a romantic partner, or a spouse. A 2016 analysis by the CDC discovered that teenage birthrates nosedived between 1991, when they reached a crisis point, and 2014, when they dropped by 60%, a record low.
Sources: en.wikipedia.org
Genetic associations include mutations in pulmonary surfactant proteins A1, A2, C (SFTPA1, SFTPA2B) and mucin (MUC5B). A remarkable aspect of the MUC5B variant is its high frequency of detection, as it is found in approximately 20% of individuals with Northern and Western European ancestry and in 19% of the Framingham Heart Study population. Mutations in human telomerase genes are also associated with familial pulmonary fibrosis and in some patients with sporadic IPF (e.g. the TERT, TERC genes). Recently an X-linked mutation in a third telomerase-associated gene, dyskerin (DKC1), has been described in a family with IPF.
The enzyme is a cytochrome P450 protein containing heme, isolated from peppermint. It requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate.
According to the Pew Research Center, 99.8% of Somalia's population is Muslim. The majority belong to the Sunni branch of Islam and the Shafi'i school of Islamic jurisprudence. Sufism, the mystical dimension of Islam, is well-established, with many congregations of various Sufi orders. It is the state religion. Christianity has around 1,000 adherents, less than 0.1% of the 2010 population. There were no Christians during early colonisation, although 100–200 followers came from the Catholic missions in British Somaliland, with no Catholic missions in Italian Somaliland. According to the Pew Research Center, less than 0.1% of Somalia's population, mainly Bantus, were adherents of folk religions.
=== Propagation === While they can be successfully propagated in early spring, epimediums are best divided in late summer, with the aim of promoting rapid re-growth of roots and shoots before the onset of winter. Several breeders (in particular Darrell Diano Probst, Tim Branney & Robin White) have also undertaken their own hybridization programmes with the genus. Various new nursery selections are gradually appearing in the horticulture trade, the best of which extend the colour and shape range of the flowers available to the gardener.
=== Creatinine clearance CCr === One method of determining GFR from creatinine is to collect urine (usually for 24 h) to determine the amount of creatinine that was removed from the blood over a given time interval. If one removes 1440 mg in 24 h, this is equivalent to removing 1 mg/min. If the blood concentration is 0.01 mg/mL (1 mg/dL), then one can say that 100 mL/min of blood is being "cleared" of creatinine, since, to get 1 mg of creatinine, 100 mL of blood containing 0.01 mg/mL would need to have been cleared. Creatinine clearance (CCr) is calculated from the creatinine concentration in the collected urine sample (UCr), urine flow rate (Vdt), and the plasma concentration (PCr). Since the product of urine concentration and urine flow rate yields creatinine excretion rate, which is the rate of removal from the blood, creatinine clearance is calculated as removal rate per min (UCr×Vdt) divided by the plasma creatinine concentration. This is commonly represented mathematically as
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.